Nature Reviews Cardiology

Article	Citations
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives	941
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions	587
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective	577
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension	533
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control	382
Environmental determinants of cardiovascular disease: lessons learned from air pollution	371
Interplay between inflammation and thrombosis in cardiovascular pathology	357
Smart wearable devices in cardiovascular care: where we are and how to move forward	332
PPAR control of metabolism and cardiovascular functions	320
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management	319
Global epidemiology of dyslipidaemias	304
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation	285
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	283
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	268
Cardiac natriuretic peptides	265
Epidemiology of cardiovascular disease in Europe	253
Pathophysiology of sepsis-induced cardiomyopathy	249
Native and bioengineered extracellular vesicles for cardiovascular therapeutics	230
Global epidemiology of valvular heart disease	230
Transportation noise pollution and cardiovascular disease	217
Self-powered cardiovascular electronic devices and systems	205
Cellular and molecular pathobiology of heart failure with preserved ejection fraction	196
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6	192
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	182
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis	179

Epicardial adipose tissue in contemporary cardiology	175
Cardiovascular disease in patients with severe mental illness	165
Ceramides and other sphingolipids as drivers of cardiovascular disease	164
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms	163
Heart failure with mid-range or mildly reduced ejection fraction	160
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes	158
The role of cardiac rehabilitation in improving cardiovascular outcomes	157
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging	147
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment	143
Systems biology in cardiovascular disease: a multiomics approach	140
Lifestyle interventions for the prevention and treatment of hypertension	131
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches	130
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity	130
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	129
Epidemiology of the inherited cardiomyopathies	127
Sit less and move more for cardiovascular health: emerging insights and opportunities	125
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy	119
Optical coherence tomography in coronary atherosclerosis assessment and intervention	119
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management	118
Pregnancy and cardiovascular disease	110
Genomics of hypertension: the road to precision medicine	105
High-density lipoproteins, reverse cholesterol transport and atherogenesis	98
Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target	98
Cardiac optogenetics: a decade of enlightenment	96
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	94
Apolipoproteins in vascular biology and atherosclerotic disease	94
Genomic frontiers in congenital heart disease	93
Transforming growth factor-β in myocardial disease	93
The role of cellular senescence in cardiac disease: basic biology and clinical relevance	91
Blood pressure and its variability: classic and novel measurement techniques	90
Catheter ablation for atrial fibrillation: current indications and evolving technologies	85
Mechanisms and consequences of endothelial cell senescence	84
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes	81
Cardiovascular risks of climate change	81
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	80
Applications of artificial intelligence in cardiovascular imaging	79
Climate change and cardiovascular disease: implications for global health	77
Cardiac involvement in the long-term implications of COVID-19	75
Vascular endothelial cell development and diversity	74
RNA-targeting and gene editing therapies for transthyretin amyloidosis	72
Sulfide regulation of cardiovascular function in health and disease	71
Bleeding avoidance strategies in percutaneous coronary intervention	71
The role of mitochondrial fission in cardiovascular health and disease	69
Myocardial stunning and hibernation revisited	69
Update on the pathophysiology and medical treatment of peripheral artery disease	69
Social determinants of atrial fibrillation	67
Epidemiology and prevention of venous thromboembolism	66
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	66
Branched-chain amino acids in cardiovascular disease	65
Clinical utility of polygenic risk scores for coronary artery disease	64

Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions	63
Epidemiology and modifiable risk factors for atrial fibrillation	63
Obesity and the risk of cardiometabolic diseases	62
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	61
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	59
Targeted delivery of therapeutic agents to the heart	58
A fresh look at coronary microembolization	57
Immune cell profiling in atherosclerosis: role in research and precision medicine	57
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs	54
The evolving cardiac lymphatic vasculature in development, repair and regeneration	54
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications	53
Pharmacogenetics to guide cardiovascular drug therapy	52
Prevention of atherosclerosis from childhood	52
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	49
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies	49
The health digital twin: advancing precision cardiovascular medicine	47
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia	47
Targeting the sarcomere in inherited cardiomyopathies	45
Hallmarks of cardiovascular ageing	43
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management	42
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	42
Electroimmunology and cardiac arrhythmia	41
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism	40
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes	38
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	38
Macrophages in cardiac remodelling after myocardial infarction	38
Obstructive sleep apnoea heterogeneity and cardiovascular disease	38
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing	37
Increasing representation and diversity in cardiovascular clinical trial populations	37
Towards precision medicine in heart failure	37
Stroke prevention strategies in high-risk patients with atrial fibrillation	36
The COVID-19 pandemic: a catalyst to improve clinical trials	36
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention	35
Remote monitoring and digital health tools in CVD management	35
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	35
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets	35
Coronary vessel formation in development and disease: mechanisms and insights for therapy	34
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease	33
Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities	33
The microtubule cytoskeleton in cardiac mechanics and heart failure	33
The contribution of the exposome to the burden of cardiovascular disease	33
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research	33
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer	31
The oral microbiome in the pathophysiology of cardiovascular disease	30
Cardiac fibroblasts and mechanosensation in heart development, health and disease	30
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	29
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome	29
Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options	29
Effects of fatty acids on T cell function: role in atherosclerosis	27
Calcific aortic valve disease: mechanisms, prevention and treatment	27
Improving clinical practice guidelines with implementation science	27
Single-cell transcriptomics for the assessment of cardiac disease	26
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention	26
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease	25
A change of heart: new roles for cilia in cardiac development and disease	25
Temporary mechanical circulatory support devices: practical considerations for all stakeholders	25
Hypertension in China: epidemiology and treatment initiatives	24
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure	24
Pathophysiology and risk factors of peripartum cardiomyopathy	24
Reduced hospital admissions for ACS — more collateral damage from COVID-19	23
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	23
Flow-induced reprogramming of endothelial cells in atherosclerosis	23
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	23
Plastics and cardiovascular disease	22
Interventional therapies for pulmonary embolism	22
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	22
The use of new CRISPR tools in cardiovascular research and medicine	21
Genetics and mechanisms of thoracic aortic disease	21
The need for increased pragmatism in cardiovascular clinical trials	21
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	19
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease	19
Long COVID and cardiovascular disease: a learning health system approach	18
Diversity 4.0 in the cardiovascular health-care workforce	18
Cardiovascular health and disease in migrant populations: a call to action	18
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges	18
Genomic enhancers in cardiac development and disease	18
Clarification of the definition of hypoplastic left heart syndrome	18
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group	17
RAAS inhibitors do not increase the risk of COVID-19	17
The role of aldehyde dehydrogenase 2 in cardiovascular disease	17

Non-hyperaemic coronary pressure measurements to guide coronary interventions	16
Developing a vaccine against atherosclerosis	16
PCSK9-targeted therapies: present and future approaches	16
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?	15
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death	15
Current and future applications of virtual reality technology for cardiac interventions	14
Mechanisms of ryanodine receptor 2 dysfunction in heart failure	14
RNA modifications in cardiovascular health and disease	14